Pfizer Inc. $PFE Shares Acquired by Canandaigua National Trust Co of Florida

Canandaigua National Trust Co of Florida lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 135.6% during the second quarter, Holdings Channel.com reports. The fund owned 36,317 shares of the biopharmaceutical company’s stock after purchasing an additional 20,901 shares during the period. Canandaigua National Trust Co of Florida’s holdings in Pfizer were worth $880,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. Trust Co of the South grew its position in Pfizer by 1.5% in the second quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company’s stock worth $712,000 after buying an additional 441 shares during the last quarter. William B. Walkup & Associates Inc. grew its position in Pfizer by 1.2% in the fourth quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company’s stock worth $1,044,000 after buying an additional 454 shares during the last quarter. Members Trust Co grew its position in Pfizer by 2.1% in the first quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company’s stock worth $587,000 after buying an additional 467 shares during the last quarter. Sutton Place Investors LLC grew its position in Pfizer by 5.6% in the first quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company’s stock worth $224,000 after buying an additional 472 shares during the last quarter. Finally, MSH Capital Advisors LLC grew its position in Pfizer by 1.4% in the first quarter. MSH Capital Advisors LLC now owns 34,585 shares of the biopharmaceutical company’s stock worth $876,000 after buying an additional 485 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of Pfizer stock opened at $23.91 on Monday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $135.94 billion, a price-to-earnings ratio of 12.72, a P/E/G ratio of 0.85 and a beta of 0.55. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43. The firm’s 50-day moving average price is $24.79 and its two-hundred day moving average price is $24.27.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period in the prior year, the business earned $0.60 earnings per share. Pfizer’s quarterly revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were issued a $0.43 dividend. The ex-dividend date was Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.2%. Pfizer’s dividend payout ratio (DPR) is 91.49%.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. HSBC decreased their price target on shares of Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a research report on Monday, May 19th. Jefferies Financial Group lifted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock a “buy” rating in a research report on Wednesday, May 21st. Berenberg Bank lowered their price objective on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research report on Thursday, May 29th. Citigroup lifted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Finally, Bank of America boosted their price target on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.